Relmada Therapeutics, Inc.
NASDAQ:RLMDBiotechnology
-$0.06 today
- Market cap
- $304.61M
- Beta
- 0.39
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$0.68
Volume 1.86M
Average 1.24M
RLMD Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Relmada Therapeutics, Inc.NASDAQ: RLMD
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $8.09M fell 32.3% year over year, ahead of the -48.6% change in trailing-twelve-month research & development. Sequentially, it rose 0.2% from the prior quarter. Over 3 fiscal years it compounded at -81.3% a year.
Context
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -32.3% holds above the trailing-twelve-month pace of -48.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 744.56K USD
- Year-over-year change
- -98.4%
- 4-year CAGR
- -69.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 744.56K | -98.4% |
| FY2024 | 2024-12-31 | 46.18M | -15.7% |
| FY2023 | 2023-12-31 | 54.81M | -51.6% |
| FY2022 | 2022-12-31 | 113.32M | +25.0% |
| FY2021 | 2021-12-31 | 90.62M | — |
Research & Development vs competitors
How RLMD compares with its peers on the latest reported figures
- RLMD's LTM Mar 2026 research & development of $23.02M is the 8th highest of the 9 companies compared; the peer median is $76.89M.
- Its year-over-year change of -48.6% is the 8th highest of 9, against a peer median of -4.9%.
- Over three fiscal years its annual growth of -81.3% compares with a peer median of +17.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $200.25M | +133.0% | +35.5% | 78.3% | |
| LTM Mar 2026 | $106.27M | -5.4% | +24.0% | 1163.2% | |
| LTM Mar 2026 | $93.8M | -4.5% | +11.6% | — | |
| LTM Mar 2026 | $86.08M | +3.9% | +4.8% | — | |
| LTM Mar 2026 | $67.7M | +8.5% | +10.6% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59.66M | -11.8% | +35.8% | — |
CBUSCibus, Inc. | LTM Mar 2026 | $41.12M | -18.1% | +56.4% | 959.3% |
| LTM Mar 2026 | $23.02M | -48.6% | -81.3% | — | |
| LTM Mar 2026 | $8.51M | -76.4% | -55.5% | 12.9% | |
| Peer median (excluding RLMD) | $76.89M | -4.9% | +17.8% | 518.8% | |
Competitors are the stored peer set for RLMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 90.62M | 113.32M | 54.81M | 46.18M | 744.56K |
| Selling, General & Admin | 35.08M | 47.93M | 48.9M | 37.72M | 311.9K |
| Operating Expenses | 125.7M | 161.25M | 103.7M | 83.89M | 59.1M |
| Depreciation & Amortization | 1.26K | 2K | 103.7M | 0 | 0 |
| EBITDA | (125.75M) | (157.04M) | 4.91M | (79.98M) | (57.39M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (125.7M) | (161.25M) | (103.7M) | (83.89M) | (59.1M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 1.2M | 2.66M | 5.15M | 3.53M | 1.4M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (48.32K) | 4.21M | 4.91M | 3.91M | 1.72M |
| Income Before Tax | (125.75M) | (157.04M) | (98.79M) | (79.98M) | (57.39M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (125.75M) | (157.04M) | (98.79M) | (79.98M) | (57.39M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (7.16) | (5.30) | (3.28) | (2.65) | (1.45) |
| EPS (Diluted) | (7.16) | (5.30) | (3.28) | (2.65) | (1.45) |
| Weighted Avg Shares | 17.55M | 29.63M | 30.1M | 30.16M | 39.48M |
| Weighted Avg Shares (Diluted) | 17.55M | 29.63M | 30.1M | 30.16M | 39.48M |
Relmada Therapeutics, Inc.
NASDAQ:RLMD
Intrinsic Alpha fair value
Locked
Current Price
$2.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.